Corcept Therapeutics Incorporated (0I3Q.L)
USD 74.43
(-7.32%)
USD 74.43
(-7.32%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - USD | -100.0% |
| 2022 | 1.14 Million USD | 117.3% |
| 2021 | 526 Thousand USD | -79.38% |
| 2020 | 2.55 Million USD | 34.05% |
| 2019 | 1.9 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 12.56 Million USD | -48.64% |
| 2014 | 24.46 Million USD | -16.57% |
| 2013 | 29.32 Million USD | 1.01% |
| 2012 | 29.03 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 6000.00 USD | -62.5% |
| 2007 | 16 Thousand USD | -44.83% |
| 2006 | 29 Thousand USD | -30.95% |
| 2005 | 42 Thousand USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 523.68 Thousand USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2024 Q3 | 6.35 Million USD | 0.0% |
| 2024 Q2 | 5.62 Million USD | 0.0% |
| 2023 FY | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 Q1 | 575 Thousand USD | -49.69% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q4 | 1.14 Million USD | 0.0% |
| 2022 Q1 | 552 Thousand USD | 4.94% |
| 2022 FY | 1.14 Million USD | 117.3% |
| 2022 Q2 | 2.26 Million USD | 310.14% |
| 2022 Q3 | - USD | -100.0% |
| 2021 FY | 526 Thousand USD | -79.38% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q4 | 526 Thousand USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2020 Q3 | 997 Thousand USD | -32.91% |
| 2020 Q1 | 1.54 Million USD | -19.02% |
| 2020 Q2 | 1.48 Million USD | -3.57% |
| 2020 Q4 | 2.55 Million USD | 155.87% |
| 2020 FY | 2.55 Million USD | 34.05% |
| 2019 FY | 1.9 Million USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | 1.9 Million USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | -100.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | 8.71 Million USD | -30.6% |
| 2016 FY | - USD | -100.0% |
| 2016 Q2 | 3.74 Million USD | -57.06% |
| 2015 FY | 12.56 Million USD | -48.64% |
| 2015 Q3 | 16.13 Million USD | -16.84% |
| 2015 Q1 | 22.12 Million USD | -9.55% |
| 2015 Q4 | 12.56 Million USD | -22.13% |
| 2015 Q2 | 19.39 Million USD | -12.32% |
| 2014 Q2 | 27.63 Million USD | -2.06% |
| 2014 Q1 | 28.21 Million USD | -3.77% |
| 2014 FY | 24.46 Million USD | -16.57% |
| 2014 Q4 | 24.46 Million USD | -5.88% |
| 2014 Q3 | 25.99 Million USD | -5.96% |
| 2013 Q1 | 28.89 Million USD | -0.47% |
| 2013 FY | 29.32 Million USD | 1.01% |
| 2013 Q2 | 30.23 Million USD | 4.64% |
| 2013 Q3 | 30.14 Million USD | -0.31% |
| 2013 Q4 | 29.32 Million USD | -2.72% |
| 2012 FY | 29.03 Million USD | 0.0% |
| 2012 Q4 | 29.03 Million USD | 2.49% |
| 2012 Q3 | 28.32 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | 4000.00 USD | -33.33% |
| 2009 Q2 | 1000.00 USD | -75.0% |
| 2009 Q3 | - USD | -100.0% |
| 2009 FY | - USD | -100.0% |
| 2008 Q2 | 12 Thousand USD | -14.29% |
| 2008 Q4 | 6000.00 USD | -33.33% |
| 2008 Q3 | 9000.00 USD | -25.0% |
| 2008 Q1 | 14 Thousand USD | -12.5% |
| 2008 FY | 6000.00 USD | -62.5% |
| 2007 Q4 | 16 Thousand USD | -15.79% |
| 2007 FY | 16 Thousand USD | -44.83% |
| 2007 Q2 | 22 Thousand USD | -15.38% |
| 2007 Q3 | 19 Thousand USD | -13.64% |
| 2007 Q1 | 26 Thousand USD | -10.34% |
| 2006 Q2 | 36 Thousand USD | -7.69% |
| 2006 FY | 29 Thousand USD | -30.95% |
| 2006 Q3 | 32 Thousand USD | -11.11% |
| 2006 Q4 | 29 Thousand USD | -9.38% |
| 2006 Q1 | 39 Thousand USD | -7.14% |
| 2005 Q2 | 10 Thousand USD | 0.0% |
| 2005 Q3 | 45 Thousand USD | 350.0% |
| 2005 Q4 | 42 Thousand USD | -6.67% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | 42 Thousand USD | 0.0% |
| 2004 Q1 | 528.89 Thousand USD | 0.99% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | -100.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | 523.68 Thousand USD | 0.0% |
| 2003 Q4 | 523.68 Thousand USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | 100.0% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 100.0% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 100.0% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 100.0% |
| bluebird bio, Inc. | 224.41 Million USD | 100.0% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 100.0% |
| Imunon, Inc. | 1.13 Million USD | 100.0% |
| Editas Medicine, Inc. | 24.37 Million USD | 100.0% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 100.0% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 100.0% |
| Myriad Genetics, Inc. | 130.9 Million USD | 100.0% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 100.0% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 100.0% |
| Verastem, Inc. | 40.08 Million USD | 100.0% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 100.0% |
| Waters Corporation | 2.3 Billion USD | 100.0% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 100.0% |
| Biogen Inc. | 7.18 Billion USD | 100.0% |
| Nektar Therapeutics | 112.62 Million USD | 100.0% |
| Perrigo Company plc | 3.63 Billion USD | 100.0% |
| Dynavax Technologies Corporation | 252.41 Million USD | 100.0% |
| Illumina, Inc. | 1.48 Billion USD | 100.0% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | 100.0% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | 100.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 100.0% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 100.0% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 100.0% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 100.0% |
| Evolus, Inc. | 120.35 Million USD | 100.0% |
| Adicet Bio, Inc. | 17.7 Million USD | 100.0% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 100.0% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 100.0% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 100.0% |
| FibroGen, Inc. | 89.69 Million USD | 100.0% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 100.0% |
| OPKO Health, Inc. | 222.03 Million USD | 100.0% |
| Homology Medicines, Inc. | 43.17 Million USD | 100.0% |
| Geron Corporation | 35.05 Million USD | 100.0% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 100.0% |
| Exelixis, Inc. | 189.94 Million USD | 100.0% |
| Viking Therapeutics, Inc. | 936 Thousand USD | 100.0% |
| Anavex Life Sciences Corp. | - USD | NaN% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 100.0% |
| Zoetis Inc. | 6.56 Billion USD | 100.0% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 100.0% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 100.0% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 100.0% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 100.0% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 100.0% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 100.0% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 100.0% |
| Blueprint Medicines Corporation | 610.96 Million USD | 100.0% |
| Insmed Incorporated | 1.19 Billion USD | 100.0% |
| TG Therapeutics, Inc. | 100.11 Million USD | 100.0% |
| Incyte Corporation | 29.16 Million USD | 100.0% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 100.0% |